Astrazeneca Plc (AZN.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2009 | 12-2008 | 12-2007 | 12-2006 | 12-2005 | |
| Sales | 32,804,000 | 31,601,000 | 29,559,000 | 26,475,000 | 23,950,000 |
| Cost of Goods | 5,775,000 | 6,598,000 | 6,419,000 | 5,559,000 | 5,356,000 |
| Gross Profit | 27,029,000 | 25,003,000 | 23,140,000 | 20,916,000 | 18,594,000 |
| Operating Expenses | 15,486,000 | 15,859,000 | 15,046,000 | 12,700,000 | 12,092,000 |
| Operating Income | 11,543,000 | 9,144,000 | 8,094,000 | 8,216,000 | 6,502,000 |
| Interest Expense | 1,198,000 | N/A | N/A | N/A | N/A |
| Other Income | 462,000 | -463,000 | -111,000 | 327,000 | 165,000 |
| Pre-tax Income | 10,807,000 | 8,681,000 | 7,983,000 | 8,543,000 | 6,667,000 |
| Income Tax | 3,263,000 | 2,551,000 | 2,356,000 | 2,480,000 | 1,943,000 |
| Net Income Continuous | 7,544,000 | 6,101,000 | 5,595,000 | 6,043,000 | 4,706,000 |
| Minority Interests | -23,000 | -29,000 | -32,000 | -20,000 | -18,000 |
| Net Income | $7,521,000 | $6,101,000 | $5,595,000 | $6,043,000 | $4,706,000 |
| EPS Basic Total Ops | 5.19 | 4.20 | 3.74 | 3.86 | 2.91 |
| EPS Basic Continuous Ops | 5.19 | 4.20 | 3.74 | 3.86 | 2.91 |
| EPS Diluted Total Ops | 5.19 | 4.20 | 3.73 | 3.85 | 2.91 |
| EPS Diluted Continuous Ops | 5.19 | 4.20 | 3.73 | 3.85 | 2.91 |
| EBITDA(a) | $14,092,000 | $11,764,000 | $9,950,000 | $9,561,000 | $7,829,000 |